Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 7/20 | 0.48 |
| ▸ | ATR | Q13535 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23714788 | 0.84 | HRH2 (0.50) | ALDH1A1KDM4ERAB9AROCK2ROCK1 | |
| SCHEMBL21812758 | 0.82 | HDAC3 (0.49) | ATRALDH1A1KDM4EL3MBTL1RAB9A | |
| SCHEMBL7125440 | 0.81 | SREBF2 (0.58) | LTA4HALDH1A1KDM4ERAB9ANPC1 | |
| SCHEMBL2585245 | 0.80 | KDM4E (0.54) | ALDH1A1KDM4ERAB9ANPC1ROCK2 | |
| SCHEMBL8216843 | 0.79 | L3MBTL1 (0.50) | ATRL3MBTL1GRM2MAPTHDAC1 | |
| SCHEMBL18664387 | 0.79 | HDAC1 (0.53) | ATRL3MBTL1GRM2HDAC1GAA | |
| SCHEMBL22216454 | 0.79 | KDM4E (0.44) | ATRALDH1A1KDM4EL3MBTL1MAPT | |
| SCHEMBL3180689 | 0.78 | L3MBTL1 (0.61) | L3MBTL1MAPTHDAC1GAAHDAC6 | |
| SCHEMBL21812750 | 0.78 | HDAC3 (0.50) | LTA4HALDH1A1KDM4EL3MBTL1RAB9A | |
| SCHEMBL506891 | 0.78 | CYP17A1 (0.61) | L3MBTL1RAB9AROCK2ROCK1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200223837-A1 | BENZOFURAN AMIDES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY | EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2020-07-16 | — | — | US | disclosed |
| US-20200223837-A1 | BENZOFURAN AMIDES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY | EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2020-07-16 | — | — | US | disclosed |
| EP-3638664-A1 | BENZOFURAN AMIDES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY | European Molecular Biology Laboratory (DE) | 2020-04-22 | — | — | EP | disclosed |
| CN-110997664-A | Benzofuran amides and heteroaromatic analogs thereof for use in therapy | 欧洲分子生物学实验室 | 2020-04-10 | — | — | CN | disclosed |
| WO-2018229193-A1 | BENZOFURAN AMIDES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY | EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2018-12-20 | — | — | WO | disclosed |
| US-8680091-B2 | 6-arylalkylamino-2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists | ELI LILLY AND COMPANY (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680091-B2 | 6-arylalkylamino-2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists | ELI LILLY AND COMPANY (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680091-B2 | 6-arylalkylamino-2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists | ELI LILLY AND COMPANY (US) | 2014-03-25 | — | — | US | disclosed |
| EP-1924561-B1 | 6-ARYLALKYLAMINO- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | LILLY CO ELI (US) | 2012-11-14 | — | — | EP | disclosed |
| EP-1924561-B1 | 6-ARYLALKYLAMINO- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | LILLY CO ELI (US) | 2012-11-14 | — | — | EP | disclosed |
| US-20110269745-A1 | 6-ARYLALKYLAMINO-2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269745-A1 | 6-ARYLALKYLAMINO-2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269745-A1 | 6-ARYLALKYLAMINO-2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2011-11-03 | — | — | US | disclosed |
| US-20080269196-A1 | 6-Arylalkylamino-2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines as 5-Ht2c Receptor Agonists | ELI LILLY AND COMPANY | 2008-10-30 | — | — | US | disclosed |
| US-20080269196-A1 | 6-Arylalkylamino-2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines as 5-Ht2c Receptor Agonists | ELI LILLY AND COMPANY | 2008-10-30 | — | — | US | disclosed |
| US-20080269196-A1 | 6-Arylalkylamino-2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines as 5-Ht2c Receptor Agonists | ELI LILLY AND COMPANY | 2008-10-30 | — | — | US | disclosed |
| WO-2007028083-A2 | 6-ARYLALKYLAMINO- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269745-A1 | 6-ARYLALKYLAMINO-2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | HTR2C, HTR1A, HTR2A | LTA4H 2179/4885ATR 4540/4885ALDH1A1 397/4885 |
| US-20080269196-A1 | 6-Arylalkylamino-2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines as 5-Ht2c Receptor Agonists | HTR2C, HTR1A, HTR2A | LTA4H 2179/4885ATR 4540/4885ALDH1A1 397/4885 |
| US-20200223837-A1 | BENZOFURAN AMIDES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY | SUCNR1, CBR1, CYP2A13 | LTA4H 1765/4885ATR 2548/4885ALDH1A1 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.